20 Nov 2023 , 02:05 PM
The US Food and Drug Administration (US FDA) has issued a warning letter to Cipla, a prominent player in the pharmaceutical industry, regarding the routine current Good Manufacturing Practices (cGMP) inspection that was carried out at its Pithampur manufacturing plant from February 6 to February 17, 2023.
This warning letter outlines infractions pertaining to procedures or controls used at the facility that do not follow the specified cGMP rules and offers instructions for making the required corrections.
The company notified the exchanges that it will reply to the Warning Letter within the allotted time frames and that it will collaborate closely with the US FDA to address the issues in a comprehensive and timely manner in order to ensure sustained compliance. ‘We uphold quality and compliance with utmost importance and remain committed to be compliant with cGMP quality standards,’ added the statement.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.